Paxman

Paxman is a global leader in the niche but impactful medical device sector of scalp cooling for chemotherapy patients. Founded in 1996, the company has established its technology as the standard of care in many regions, supported by extensive clinical evidence and inclusion in major oncology guidelines. Its commercial focus is on expanding global market access, securing reimbursement (notably with new U.S. CPT codes), and continuing research to improve efficacy, particularly for challenging chemotherapy regimens like anthracyclines. The company operates as a mission-driven, likely private entity with a deep personal connection to the patient community it serves.

Mechanized scalp cooling (cryotherapy) system that reduces blood flow and metabolic activity in hair follicles to minimize chemotherapy drug uptake and prevent alopecia.

Paxman operates in the niche medical device market for scalp cooling, competing with other cap-based cooling systems (both manual and mechanized). It differentiates itself as the pioneer with over 25 years of experience, a strong global footprint in over 60 countries, and a substantial body of clinical evidence supporting its technology. The recent U.S. CPT code achievement is a significant competitive moat.